HedgeChatter

  • Home /
  • Tag Archives

HZNP

Horizon Pharma to Present at the Cowen and Company 34th Annual Health Care Conference

[Marketwired] – Horizon Pharma, Inc. today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference on Monday, March … moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click here to view […]

February 24, 2014 Bystocknews , Comments Off on Horizon Pharma to Present at the Cowen and Company 34th Annual Health Care Conference read more

4:41 pm Horizon Pharma announced that the FDA joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee was split on whether the data show adequate differences in cardiovascular risk among NSAIDs to support l

moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on 4:41 pm Horizon Pharma announced that the FDA joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee was split on whether the data show adequate differences in cardiovascular risk among NSAIDs to support l read more

4:41 pm Horizon Pharma announced that the FDA joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee was split on whether the data show adequate differences in cardiovascular risk among NSAIDs to support l

moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on 4:41 pm Horizon Pharma announced that the FDA joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee was split on whether the data show adequate differences in cardiovascular risk among NSAIDs to support l read more

Horizon Pharma Provides Update on February 10-11, 2014 FDA Joint Advisory Committee Meeting on Cardiovascular Risk of NSAIDs

[Marketwired] – Horizon Pharma, Inc., , a commercial stage, specialty pharmaceutical company that markets two gastroprotective nonsteroidal anti-inflammatory drugs , VIMOVO® and DUEXIS® , announced that the FDA joint … moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on Horizon Pharma Provides Update on February 10-11, 2014 FDA Joint Advisory Committee Meeting on Cardiovascular Risk of NSAIDs read more

Horizon Pharma Reports 2012 Financial Results and Provides Business Update

[at noodls] – Conference Call and Webcast Today, March 18th, at 8:00 a.m. ET DEERFIELD, IL — (Marketwire) — 03/18/13 — Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company’s business and announced … moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click […]

March 18, 2013 Bystocknews , Comments Off on Horizon Pharma Reports 2012 Financial Results and Provides Business Update read more

Horizon Pharma to Present at the 25th Annual ROTH Conference

[at noodls] – DEERFIELD, IL — (Marketwire) — 03/11/13 — Horizon Pharma, Inc. (NASDAQ: HZNP), today announced that Timothy P. Walbert, chairman, president and chief executive officer will present at the 25th Annual … moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click here to view […]

March 11, 2013 Bystocknews , Comments Off on Horizon Pharma to Present at the 25th Annual ROTH Conference read more

Horizon Pharma Receives Marketing Authorization for DUEXIS(R) From the United Kingdom Medicines and Healthcare Products Regulatory Agency

[at noodls] – DEERFIELD, IL — (Marketwire) — 03/07/13 — Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing … moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click here to view […]

March 7, 2013 Bystocknews , Comments Off on Horizon Pharma Receives Marketing Authorization for DUEXIS(R) From the United Kingdom Medicines and Healthcare Products Regulatory Agency read more

Horizon Pharma Announces Preliminary Fourth Quarter and Full Year 2012 Revenues, Full U.S. Commercial Launch of RAYOS(R) (Prednisone) Delayed-Release Tablets and Approval of LODOTRA(R) in South Korea

[at noodls] – DEERFIELD, IL — (Marketwire) — 02/11/13 — Horizon Pharma, Inc. (NASDAQ: HZNP) today announced preliminary (unaudited) revenues for the fourth quarter and fiscal year ended December 31, 2012. Full year … moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click here to view […]

February 11, 2013 Bystocknews , Comments Off on Horizon Pharma Announces Preliminary Fourth Quarter and Full Year 2012 Revenues, Full U.S. Commercial Launch of RAYOS(R) (Prednisone) Delayed-Release Tablets and Approval of LODOTRA(R) in South Korea read more

Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets

[at noodls] – DEERFIELD, IL — (Marketwire) — 02/06/13 — Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) … moreView todays social media effects on HZNPView the latest stocks trending across Twitter. Click to view dashboardSee who Horizon is hiring next, click here to […]

February 6, 2013 Bystocknews , Comments Off on Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets read more